E-course: Male hypogonadism: Testosterone therapy is not dangerous
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
This e-course will be of great educational value for urologists as internationally-known experts will focus on the controversial and challenging areas of this rapidly evolving field, and provide you with vital insights.
Testosterone replacement therapy is indicated in a variety of clinical conditions and has shown to improve the quality of life in patients with hypogonadism. In addition, the therapy may also have other beneficial effects on long-term cardiovascular health. However, patients receiving testosterone replacement therapy should be fully counselled on the risks and advantages of the treatment.
The e-course will discuss the current EAU Guidelines and the evidence base for treating men with hypogonadism, as well as highlight controversial areas. The expert discussion will also provide an up-to-date guidance on the safety profile of testosterone replacement therapy focusing on the potential long-term cardiovascular effects and the potential risks on prostate health. The e-course will also highlight and discuss the effects of testosterone on bone metabolism.
Speakers:
- Dr. G. Corona (IT)
- Dr. P. Capogrosso (IT)
- Prof. A. Salonia (IT)
- Prof. S. Minhas (GB)
- Prof. T.H. Jones (GB)
This e-course is brought to you in collaboration with the EAU Guidelines office.